InvestSMART

Cleo Diagnostics Ltd (ASX:COV)

ALERT: Price-sensitive ASX Announcement for COV
Current share price for COV : $0.320 -0.01 (-3.03%)+
Announcement
Release
20 Aug 2026 3:52PM
Price at Release
$0.330
Full Release
download
Summary
Cleo Diagnostics Ltd reported a comprehensive loss of $5,936,480 for the financial year ending on 30 June 2026, with significant research and development expenditures contributing to this result. The company recognized $1,717,150 in government grants as part of its income and had an increased issued capital of $18,169,225 due to equity contributions. Despite the year-end cash balance being $6,223,995, no income tax was charged against the company due to existing tax losses. They also had a total of 15,804,583 options outstanding. Key members of the board included non-executive and executive directors such as A. M. Wing, R. Allman, and others.
Key Points
  • Cleo Diagnostics reported a comprehensive loss of $5,936,480 for the year ended 30 June 2026.
  • The company's revenue included government grants totaling $1,717,150.
  • Cleo Diagnostics had a total of 15,804,583 options outstanding by the end of the financial year.
  • The company's issued capital increased to $18,169,225 following contributions of equity.
  • Research and development expenditure for the year amounted to $4,916,424.
  • The company's basic and diluted earnings per share were both -4.47 cents.
  • The company had total assets of $6,680,903 and liabilities of $1,670,888.
  • No income tax expense was recorded due to tax losses.
  • The directors included A. M. Wing, R. Allman, A. N. Stephens, T. W. Jobling, and L. J. Nolan.
  • Cleo Diagnostics had a cash balance of $6,223,995 at the end of the financial year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.